Time to castration-resistance and docetaxel outcomes in metastatic prostate cancer.

e16519Background: Castration resistant prostate cancer (CRPC) continues to present a challenge for oncologists. There is renewed interest in the use of docetaxel in advanced prostate cancer; howeve...